Opportunistic infections--coming to the limits of immunosuppression?

• Published in: Cold Spring Harbor perspectives in medicine 2013-10, Vol.3 (10), p.a015669-a015669
• Main Author: Fishman, Jay A
• Format: Article
• Language: English
• Subjects: Antibiotic Prophylaxis - adverse effects; Graft Rejection - immunology; Humans; Immunity, Cellular - immunology; Immunosuppression - adverse effects; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - immunology; Microbiota - immunology; Opportunistic Infections - chemically induced; Opportunistic Infections - immunology; Opportunistic Infections - prevention & control; Risk Factors; Tissue Donors; Transplantation - adverse effects; Transplantation Immunology - immunology
• ISSN: 2157-1422; 2472-5412
• DOI: 10.1101/cshperspect.a015669

Possible etiologies of infection in the solid organ recipient are diverse, ranging from common bacterial and viral pathogens to opportunistic pathogens that cause invasive disease only in immunocompromised hosts. The recognition of infectious syndromes in this population is limited by alterations in the clinical manifestations by immunosuppression. The risk of serious infections in the organ transplant patient is determined by the interaction between the patients' recent and distant epidemiological exposures and all factors that contribute to the patient's net state of immune suppression. This risk is altered by antimicrobial prophylaxis and changes in immunosuppressive therapies. In addition to the direct effects of infection, opportunistic infections, and the microbiome may adversely shape the host immune responses with diminished graft and patient survivals. Antimicrobial therapies are more complex than in the normal host with a significant incidence of drug toxicity and a propensity for drug interactions with the immunosuppressive agents used to maintain graft function. Rapid and specific microbiologic diagnosis is essential. Newer microbiologic assays have improved the diagnosis and management of opportunistic infections. These tools coupled with assays that assess immune responses to infection and to graft antigens may allow optimization of management for graft recipients in the future.